Author Correction: Evaluation of Potential Drug-Drug Interactions in the Intensive Care Unit.

Correction to: Eur Rev Med Pharmacol Sci 2021; 25 (18): 5801-5806-DOI: 10.26355/eurrev_202109_26798-PMID: 34604971 published online on September 30, 2021. The methodology section of this research article incorrectly stated that the lexi-interact checker program is freely accessible.

Outcome of carbapenem or colistin resistant Klebsiella pneumoniae bacteremia in the intensive care unit.

Carbapenem-resistant Klebsiella pneumoniae (CRKp) infections continue to be an important cause of mortality. In this retrospective study, the effect of carbapenem or colistin resistance on mortality in Klebsiella pneumoniae bacteremia and combined meropenem + colistin administration in CRKp bacteremia was evaluated. In addition to that, a mathematical model is applied to explore the relationships between the resistance and mortality.

Sepsis episodes caused by pressure injuries in critical illness: a retrospective observational cohort study.

Background: Critically-ill patients (CIPs) with pressure injuries (PIs) may develop bloodstream infections (BSIs).

Purpose: To identify predisposing factors and discuss diagnosis and management of sepsis-related PIs in CIPs.

Methods: The records of CIPs in the intensive care unit (ICU) between January 1, 2014, and January 1, 2020, with PI with sepsis-diagnoses and with different site cultures that were positive concurrent with bloodstream-cultures were retrospectively reviewed.

OXA-48 Dominance Meets Ceftazidime-Avibactam: A Battle Against Life-Threatening Carbapenem-Resistant Klebsiella pneumoniae Infections in the Intensive Care Unit.

Objective In this study, we aimed to describe the outcomes in ICU patients with bloodstream infection (BSI) or ventilatory-associated pneumonia (VAP) due to carbapenem-resistant (CRKP) who received ceftazidime-avibactam treatment at a tertiary care university hospital. Methods Patients aged 18 years or older who were admitted to the Anesthesiology and Reanimation ICU at Bursa Uludag University Faculty of Medicine Hospital between June 13, 2021, and July 16, 2023, and diagnosed with BSI or VAP due to CRKP were included in this study. Results A total of 42 patients treated with ceftazidime-avibactam were included.